CK37

Overview

CK37 is a competitive choline kinase-α inhibitor. CK37 inhibits purified recombinant human choline kinase-α activity. CK37 suppresses MAPK and PI3K/AKT signaling, disrupts actin cytoskeletal organization. CK37 diminishs activating phosphorylations of ERK . CK37 exhibits anticancer activity against cervical cancer , melanoma, Lewis lung carcinoma, lung adenocarcinoma, breast cancer , and leukemia.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Cervical Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Lung Adenocarcinoma | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Arp2/3 Complex | Products > Signaling Pathways > PERK | Products > Signaling Pathways > Choline Kinase | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > PI3K

Product Information

• Catalog No.: HY-101145
• CAS No.: 1001478-90-5
• Molecular Formula: C20H22N4OS
• Molecular Weight: 366.48
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source